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In Thrombolysis in Myocardial Infarction (TIMI) Phase I, 
290 patients with acute myocardial infarction were ran- 
domized to either intravenous recombinant tissue-type plas- 
minogen activator @t-PA) or intravenous streptokinase. 
Two hundred twenty-nine patients had radionuclide ven- 
triculograms at discharge for assessment of global and 
regional left ventricular ejection fraction. Among these 229 
patients 185 had totally occluded infarct-related arteries, 
and angiographic reperfusion of the infarct-related artery 
occurred in 69% of patients treated with rt-PA and 28% of 
patients treated with streptokinase (p < 0.001). 
Mean global left ventricular ejection fraction was not 
different for rt-PA-treated patients compared with strep 
tokinase-treated patients (0.46 versus 0.45). However, the 
average regional ejection fraction of the regions subtended 
by the infarct-related artery showed a trend toward better 
average infarct region ejection fraction in patients treated 
with rt-PA than in patients treated with streptokinase (0.40 
versus 0.36; 0.05 < p < 0.06). Analysis of data according to 
perfusion status of the infarct-related artery showed no 
difference in mean global left ventricular ejection fraction 
between patients with sustained versus nonsustained reper- 
fusion (0.47 versus 0.44). However, there was better aver- 
age regional ejection fraction of the region subtended by the 
infarct-related artery in patients with sustained reperfusion 
(0.40 versus 0.36; p < 0.01). 
Thus, quantitation of regional left ventricular function 
by radionuclide techniques provides a noninvasive means 
for evaluating the effects of thrombolysis. This study sug- 
gests a direct relation between improvement of regional left 
ventricular function and the greater infarct-related artery 
patency rate achieved by rt-PA compared with streptoki- 
nase. 
(.I Am Co11 Cardiol1989;13:998-1005) 
The Thrombolysis in Myocardial Infarction (TIMI) trial has 
been in progress since August 1984. Phase I, completed in 
February 1985, was conducted to establish the relative 
thrombolytic attributes of intravenous recombinant tissue- 
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type plasminogen activator (rt-PA) in comparison with intra- 
venous streptokinase with use of coronary angiographic 
evidence of infarct-related vessel patency as the primary 
study end point. In the TIM1 Phase I trial, it was demon- 
strated that significantly greater recanalization rates oc- 
curred after treatment with rt-PA than with streptokinase (l- 
3). This difference was observed earlier than expected, and 
the study was terminated before the anticipated total patient 
enrollment was achieved. During the course of the study, 
contrast and radionuclide angiocardiography were per- 
formed to provide secondary end point information concern- 
ing the effect of therapy on left ventricular function. 
According to protocol, cardiac catheterization and contrast 
ventriculography were performed before therapy and again 
at hospital discharge, whereas radionuclide angiocardiogra- 
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phy was performed only at the time of hospital discharge. 
The results of contrast left ventricular angiography in Phase 
1 have been reported (4). 
The present report describes the results of radionuclide 
assessment of left ventricular function in TIMI Phase I 
patients at hospital discharge. Global function was defined 
by left ventricular ejection fraction, whereas regional func- 
tion was measured by regional count-based ejection fraction. 
These functional variables are compared in patients receiv- 
ing rt-PA and in those receiving streptokinase, as well as in 
patients with and without successful reperfusion. 
Methods 
Study patients. The TIMI protocol has been described in 
detail previously (3). Patients were included in the Phase 1 
TIM1 trial if they had chest pain lasting ~30 min, and ST 
segment elevation ~0.1 mV in at least two leads on the 
admission electrocardiogram (ECG). If more than 7 h had 
elapsed since the onset of chest pain, patients were not 
eligible. Other exclusion criteria were age >75 years, uncon- 
trolled hypertension, cerebrovascular events, severe strep- 
tococcal infection, other advanced illness, previous strepto- 
kinase infusion, severe trauma within the last 6 months, 
current oral anticoagulant therapy, past or present bleeding 
disorder or significant gastrointestinal bleeding, surgery or 
cardiopulmonary resuscitation within the 2 weeks preceding 
admission, prior coronary artery bypass surgery, left bundle 
branch block, prosthetic heart valve, dilated cardiomyopa- 
thy and shock unresponsive to volume expansion or vaso- 
pressor therapy. 
After providing informed consent, eligible patients were 
immediately transferred to the cardiac catheterization labo- 
ratory. A 5,000 U intravenous bolus of heparin was given. 
Left ventriculography was performed in the 30” right anterior 
oblique projection. Angiograms of the noninfarct- and in- 
farct-related coronary arteries (as judged from ECG and 
regional wall motion abnormality on the ventriculogram) 
were obtained in multiple views. Patients with ~50% diam- 
eter reduction of the infarct-related artery at baseline study 
or after intracoronary nitroglycerin (200 pg) were not given 
thrombolytic agents. The remaining patients were assigned 
to either streptokinase (Hoechst-Roussel Pharmaceuticals or 
Kabi Vitrum) or rt-PA (Genentech, Inc.). Streptokinase was 
administered as 1.5 million U intravenously over 1 h. Roller 
bottle method-produced rt-PA (GII021) was given intrave- 
nously over a 3 h period: 40,20 and 20 mg in the I st, 2nd and 
3rd h, respectively. To maintain blinding, each patient 
received both an active agent and a placebo in concomitant 
1 and 3 h infusions through separate intravenous lines. A 
coronary angiogram of the infarct-related artery was ob- 
tained 10, 20. 30. 45. 60, 75 and 90 min after initiation of 
thrombolytic therapy. Coronary angiography and ventricu- 
lography were repeated at the time of hospital 
(usually 8 to IO days after infarction). 
999 
discharge 
After coronary angiography during the acute phase of 
infarction, the patients received routine coronary care plus 
intravenous heparin at 1,000 U/h beginning 3 h after the 
initial bolus with the dose adjusted as needed to maintain 
partial thromboplastin time at 1.5 to 2 times normal for 5 
days. ,411 other therapies were administered according to 
guidelines written in the TIM1 Manual of Operations: these 
guidelines specifically addressed antiarrhythmic agents (for 
example, lidocaine) and antianginal agents (for example, 
nitrates, beta-adrenergic blockers and calcium channel 
blockers). No important differences existed in concomitant 
therapies between the double-blind randomized treatment 
groups. 
Radionuclide angiocardiography. Equilibrium radionu- 
elide angiocardiography was performed before hospital dis- 
charge (mean 9.6 days after study entry). In all I3 partici- 
pating centers. the procedure was performed according to a 
standardized protocol. The patients’ own red blood cells 
were labeled with technetium-99m with use of a modified in 
vivo technique: 15 min after injection of stannous pyrophos- 
phate (SO mg intravenously). IO cc of blood was withdrawn 
into a syringe containing 30 mCi of technetium-99m pertech- 
netate and 1 ml of anticoagulant citrate dextrose solution. 
The blood was incubated in the syringe for IO min, and then 
reinjected into the patient with saline flush (5). Radionuclide 
angiocardiography was performed with a scintillation cam- 
era equipped with a general, all purpose. parallel hole 
collimator interfaced with a dedicated minicomputer. The 
energy window (20%) was set over 140 keV. Image acquisi- 
tion was done in four projections: left anterior oblique 
projection (angulation that best separated the right and left 
ventricles), anterior projection (45” to the right of the angu- 
lation for the left anterior oblique projection), left lateral 
projection (with the patient lying on the right side and the 
gamma detector in the same angulation as for the anterior 
view) (6) and left posterior oblique projection (30” posterior 
of the left lateral projection). All data were acquired in 
ECG-synchronized frame mode in 64 x 64 matrix (word 
mode). At least 16 frames/RR interval were acquired. Each 
frame was ~40 ms. The unsmoothed studies were stored on 
magnetic tape or floppy disk and mailed to the radionuclide 
core laboratory at Yale University for analysis. 
Quantitative analysis. The studies analyzed in the radio- 
nuclide core laboratory were identified only by code name 
and number; no clinical information was provided. In the 
radionuclide core laboratory, studies were transcribed to a 
central computer for temporal and spatial filtering and dis- 
played as an endless loop movie. 
Glohrrl and regional variables for kft ventricular function 
M’ere dcrilmi ,from the equilibrium radionwlide angio- 
graphic studies : 
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Figure 1. Computer display of regional (REG) left ventricular ejec- 
tion fraction on left anterior oblique view radionuclide angiocardio- 
graphic image. The end-diastolic perimeter is displayed as a semi- 
circle superimposed on the end-systolic perimeter. Regional left 
ventricular ejection fraction (EF) is determined from end-diastolic 
(DIAS) and end-systolic (SYST) counts in five segments: apical 
septal (AS), basal septal (BS), inferoapical (IA), inferolateral (IL) 
and posterolateral (PL). 
1) Global left ventricular ejection fraction was determined 
from the left anterior oblique projection. with use of 
previously validated automated computer software (Gen- 
eral Electric, PAGE) (7). In brief, after filtering of the 
images, the center of the left ventricle is automatically 
found by the computer. From this center, the left ventric- 
ular perimeter (second derivative points) is identified 
along radii in each frame of the cardiac cycle. Correction 
for background activity is performed by interpolative 
subtraction. Finally, a left ventricular volume curve is 
generated over the regions of interest of the left ventricle. 
From this curve, global left ventricular ejection fraction is 
calculated in the standard fashion: (end-diastolic counts 
minus end-systolic counts)/end-diastolic counts. 
2) Regional left ventricular ejection fraction was obtained 
from the left anterior oblique projection by dividing the 
end-diastolic region of interest in five segments: basal 
septal, apical septal, inferoapical, inferolateral and pos- 
terolateral. The area involving the valve plane was ex- 
cluded (Fig. 1). Regional ejection fraction was calculated 
from maximal and minimal counts in all regions. 
For each patient, the average regional ejection fraction 
of the myocardial infarct zone also was determined. This 
value was based on the relation between the location of the 
sector of the left anterior oblique left ventricular blood pool 
used for the regional ejection fraction and the anatomic 
location of the infarct. For right coronary artery-related 
infarcts, the average of the inferoapical and inferolateral 
segments was chosen. For left anterior descending artery- 
related infarcts, an average of the basal septal and apical 
septal regions was chosen, and for left circumflex artery- 
related infarcts, the posterolateral segment was chosen. For 
the entire group, with use of this technique, an average of the 
myocardial infarct zone regional ejection fractions could 
then analyze regional function as it related to the infarct zone 
alone. 
Angiographic and clinical definitions. The degree of cor- 
onary reperfusion after thrombolytic therapy and the extent 
of collateral vesselformation on the angiograms were graded 
(grade 0, 1, 2 or 3) according to standardized criteria in the 
TIMI trial (l-4). 
Reperfusion status. Sustained reperfusion was defined as 
follows: coronary perfusion was grade 2 or 3 at 90 min after 
initiation of treatment and at hospital discharge, and there 
were no reocclusion events (angiographic occlusion or clin- 
ical reinfarction) for 21 days after the onset of chest pain. 
Alternatively, coronary perfusion was grade 2 or 3 at 90 min 
after initiation of thrombolytic therapy, there were no angio- 
graphic data at discharge and no reinfarction occurred 
clinically for 21 days after the onset of chest pain. 
Nonsustained reperjiuion was defined by the presence of 
one of the following variables: 1) reocclusion event, 2) death 
within 21 days of the onset of chest pain, or 3) grade 0 or 1 
perfusion at 90 min after initiation of thrombolytic treatment 
or at hospital discharge. 
Data analysis. Global and regional left ventricular func- 
tion were compared with respect to type of thrombolytic 
agent used. Because the response of these variables depends 
on the success or failure of thrombolytic therapy, they were 
also analyzed in relation to reperfusion status of the infarct- 
related artery. Moreover, because the impact of successful 
reperfusion on global and regional left ventricular function 
may depend on which artery is infarct-related, these varia- 
bles were also analyzed in relation to reperfusion status of 
the specijk infarct-related artery (left anterior descending, 
left circumflex or right coronary artery). 
Because TIMI Phase I was designed to detect differences 
in reperfusion regardless of infarct-related artery and was 
stopped early because of large differences in reperfusion 
rates favoring rt-PA, there are too few observations for each 
region of the myocardium and for each infarct-related artery 
to analyze regional wall motion in each area with appropriate 
statistical power. On the basis of experience with reliability 
of global ejection fraction measurements obtained with 
radionuclide ventriculography in patients with a normal or 
abnormal ejection fraction (7), a “trend” in global or re- 
gional wall motion has been arbitrarily defined as a differ- 
ence of r3 units if associated with a probability (p) value 
~0.10. These p values are provided as descriptive statistics 
with no adjustment for multiple comparisons. 
To summarize the effects of treatment on regional ejec- 
tion fraction for the ventricular wall segments associated 
with the infarct-related artery, a regression analysis (8) was 
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performed with t/w following model: regional ejection frac- 
tion = a constant intercept t treatment effect t infarct- 
related artery effect + random error. The treatment effect 
analyzed with this model compared streptokinase and rt-PA. 
Also compared with this model were sustained reperfusion 
with nonsustained reperfusion and collateral circulation 
present with no collateral circulation present. The infarct- 
related artery is included in this model as a covariate 
because of large differences in regional ejection fraction 
associated with the three infarct-related coronary arteries. 
To attempt to account jbr (111 treated patients. a method 
for imputing missirrg data (9, IO) on global qjec’tion fraction 
values ~‘as employed as follo~~s: 0.00 for patients deceased 
within 10 days of entry: 0.30 for patients with clinical signs of 
reocclusion, coronary angioplasty or coronary bypass sur- 
gery and a value derived from a regression equation for 
patients who had contrast ventriculography only. This re- 
gression equation for left ventricular ejection fraction 
(LVEF) was based on 166 pairs of patients who had both 
contrast and radionuclide ventriculography (r = 0.74: 
LVEF = 0.86 x contrast LVEF + 2.90). In 16 patients, 
contrast ventriculograms were either not available or tech- 
nically inadequate. Therefore. data could not be imputed in 
6% of patients. 
All measured radionuclide angiographic variables were 
sent on standardized forms to the TIMI Coordinating Center 
at the Maryland Medical Research Institute, Baltimore, 
where all statistical analysis was performed. Data are ex- 
pressed as mean values i SD. Differences in mean values 
between two groups were analyzed by I test (IO). Differences 
in categorical variables between two groups were analyzed 
by chi-square test (IO). A p value co.05 (two-tailed) was 
considered statistically significant. 
Results 
Patient characteristics (Table 1). Two hundred ninety 
patients with acute myocardial infarction were treated ac- 
cording to random assignment in TIM1 Phase I with either 
intravenous rt-PA (n = 143) or intravenous streptokinase 
(n = 147). Two hundred twenty-nine patients (79%) had a 
radionuclide ventriculogram at hospital discharge. The 61 
patients without a discharge radionuclide ventriculogram 
included 12 patients who died during the first 21 days after 
infarction, 12 who had coronary bypass surgery in this 
period and 37 who either did not undergo radionuclide study 
or had an inadequate study because of technical difficulties. 
The clinical characteristics of the 290 patients with or 
without a discharge radionuclide study are summarized in 
Table 1. Patients with this study had a greater frequency of 
clinically sustained reperfusion and fewer cardiac events 
than did those who were not studied. 
Results of thrombolytic therapy (Table 2). Among the 229 
patients with a discharge radionuclide ventriculogram, 185 
Table 1. Comparison of Clinical and Angiographic Variables in 
290 Patients With and Without Radionuclide Ventriculographic 
Data 
Patients With Other 
LVEF Data Patients P 
No.’ 219 61 
Age (yr) (mean) 56.X -58.3 
Male (g) X3.1) 67.2 0.007 
History of previous Ml (55) 16.2 14.6 
Time. pain to treatment th) (mean) 4.x 4.4 
Baseline measurements 
No. of diseased vessels (‘lr)? 
I 66.X 57.4 
, 24.Y 76.2 
3 x.3 16.4 
Infarct artery (5 1 
LAD 44.5 39.3 
KCA 44. I 47.5 
LCX Il.4 13.1 
Collateral vessels (5:) 31.0 34.4 
Infarct artery evaluation 
Pretreatment grade of 0 or I In) I85 47 
Repetfttsion at 90 min t%i) 48. I -38.3 
Reperfusion status 
Sustained reperfusion t%)i 46.7 26.2 0.004 
Event, before ?I days 
Death (RI 0.9 lY.7 10.001 
CABG (‘/;I 9.1 19.7 0.02 
Reinfarction I%) 9.6 ‘3.0 0.005 
*Applies to all percents except reperfusion at 90 min: *percent of patients 
with one. two or three vessels with stenosis >70%: fgrade ? or 3 perfusion at 
90 min. no reocclusion events for 21 days after the onset of chest pain and no 
occlusion found at hospital discharge. If not indicated, p = NS. CABG = 
coronary artery bypass grafting; LAD = left anterior descending coronary 
artery: LCx = left circumflex coronary artery; LVEF = left ventricular 
ejectton fraction: MI = myocardial infarction: RCA = right coronary artery. 
had totally occluded infarct-related arteries (grade 0 or I) at 
presentation. Of these 185 patients, 90 treated with rt-PA 
had significantly more frequent angiographic reperfusion of 
the infarct-related artery than did the 95 patients treated with 
streptokinase (69% versus 287~~ p < 0.001). These reperfu- 
sion rates are similar to those observed in the entire study 
group of 290 patients (I ,3). The time from onset of chest pain 
to treatment was not different for the two groups (4.8 versus 
4.9 h. p = NS). The clinical and angiographic variables of 
both treatment groups and the time to onset of treatment are 
shown in Table 2. Among patients for whom radionuclide 
left ventricular ejection fraction was obtained. treatment 
with rt-PA resulted in a significantly higher frequency of 
reperfusion of the infarct-related artery than that obtained 
with streptokinase in patients treated <4 h and r4 h after the 
onset of chest pain. 
Effect of thrombolytic therapy on global and regional left 
ventricular function at hospital discharge (Tables 3 and 4). 
Despite differences in reperfusion rates noted in the two 
treatment groups, mean global left ventricular ejection frac- 
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Table 2. Comparison of Clinical and Angiographic Variables by Treatment and Time From Onset to Treatment in 229 Patients With 
Radionuclide Ventriculographic Data 
Treatment <4 h 24 h 
rt-PA SK P rt-PA SK P rt-PA SK P 
No.* 
Age (yr) (mean) 
Male (%) 
History of previous MI (%) 
Time, pain to treatment (h) (mean) 
Baseline measurements 
No. of vessels diseased (%)t 
2 
3 
Infarct artery (%) 
LAD 
RCA 
LCX 
Collateral vessels (%) 
Infarct artery evaluation 
Pretreatment grade of 0 or I (n) 
Reperfusion at 90 min (%) 
Reperfusion status 
Sustained reperfusion (%)$ 
Events within 21 days 
Death (7~) 
CABG (%) 
Reinfarction (%) 
114 II5 38 36 76 79 
55.6 51.9 56.4 56.2 55.2 58.6 0.04 
83.3 82.6 89.5 91.7 80.3 78.5 
14.0 18.3 15.8 19.4 13.2 17.7 
4.8 4.9 3.2 3.1 5.6 5.7 
64.9 68.7 65.8 12.2 64.5 67.1 
28.1 21.7 28.9 22.2 27.6 21.5 
7.0 9.6 5.3 5.6 7.9 11.4 
43.9 45.2 57.9 44.4 36.8 45.6 
46.5 41.7 31.6 44.4 53.9 40.5 
9.6 13.0 10.5 II.1 9.2 13.9 
27.2 34.8 26.3 30.6 27.6 36.1 
90 95 29 34 61 61 
68.9 28.4 <O.OOl 75.9 47.1 0.02 65.6 18.0 <O.OOl 
60.5 33.0 <O.OOl 71.1 44.4 0.02 55.3 27.8 0.001 
0.0 1.7 0.0 2.8 0.0 1.3 
11.4 7.0 15.8 5.6 9.2 7.6 
12.3 7.0 10.5 2.8 13.2 8.9 
*Applies to all percents except reperfusion at 90 min: tpercent of patients with one, two or three vessels with stenosis >70%; $grade 2 or 3 perfusion at 90 
min. no reocclusion events for 21 days after the onset of chest pain and no occlusion found at hospital discharge. If not indicated p = NS. r&PA = recombinant 
tissue-type plasminogen activator; SK = streptokinase; other abbreviations as in Table I. 
tion at discharge was not different for patients treated with 
rt-PA or streptokinase (0.46 versus 0.45, p = NS) (Table 3). 
Imputed global ejection fraction included data from 274 
patients (94%) in the analysis, and was not different in the 
two groups (0.44 versus 0.42, p = NS). 
However, mean regional left ventricular ejection fraction 
in the apical septal area tended to be better in patients 
treated with rt-PA than in those treated with streptokinase 
(0.39 versus 0.35, p = 0.06). Similarly, there was a trend 
toward better inferoapical mean regional left ventricular 
ejection fraction in patients treated with r&PA than in those 
treated with streptokinase (0.43 versus 0.38, p = 0.08). 
The impact of treatment was further evaluated according 
to the speci’c infarct-related artery (Table 4). There were no 
appreciable differences in global ejection fraction in any 
arterial distribution. There was a regional ejection fraction 
trend in the apical septal region (0.45 versus 0.39, p = 0.09) 
favoring treatment with rt-PA over treatment with strepto- 
Table 3. Left Ventricular Ejection Fraction at Predischarge by Treatment and Perfusion Status in 229 Patients 
Treatment Perfusion Status 
Left Ventricular 
Ejection Fraction rt-PA Streptokinase Sustained Nonsustained 
No. of patients 114 115 107 122 
Global* 0.46 ? 0.13 0.45 + 0.13 0.47 + 0.13 0.44 * 0.13 
Regional 
Basal septal 0.36 + 0.17 0.35 + 0.18 0.34 * 0.17 0.36 + 0.17 
Apical septal 0.39 ? 0.18 0.35 + 0.17 0.38 2 0.18 0.36 ? 0.16 
Inferoapical 0.43 + 0.19 0.38 + 0.18 0.43 + 0.20 0.38 + 0.17 
Inferolateral 0.50 2 0.20 0.46 ? 0.20 0.52 + 0.20 0.45 + 0.19 
Posterolateral 0.57 ? 0.16 0.54 + 0.17 0.58 + 0.16 0.53 + 0.17 
*Imputed global left ventricular ejection fraction (see text) was as follows: rt-PA = 0.44 + 0.16 (n = 133), streptokinase 0.42 + 0.15 (n = 141), p = NS. 
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Table 4. Left Ventricular Ejection Fraction at Predischarge by 
Treatment in 229 Patients 
Table 5. Global and Regional Left Ventricular Ejection Fraction 
at Predischarge by Collateral Vessel Status in 229 Patients 
Infarct Artery and Left 
Ventricular Ejection Fraction 
Treatment 
II-PA Streptokinase 
Left Ventricular 
Collateral Vessel Status 
Ejection Fraction Some None 
Right coronary artery 
No. of patients 
Global 
Regional 
Basal septal 
Apical septal 
lnferoapical 
Inferolateral 
Posterolateral 
Left anterior descending artery 
No. of patients 
Global 
Regional 
Basal septal 
Apical septal 
lnferoapical 
lnferolateral 
Posterolateral 
Left circumflex coronary artery 
No. of patients 
GlObdl 
Regional 
Basal septal 
Apical septal 
Inferoapical 
lnferolateral 
Posterolateral 
53 
0.52 ? 0.13 
0.43 + 0.15 
0.45 a 0.16 
0.48 t 0.17 
0.54 + 0.18 
0.60 lr 0.14 
50 
0.40 c 0.12 
0.25 2 0.13 
0.30 2 0.17 
0.36 ? 0.20 
0.49 + 0.21 
0.55 2 0.16 
11 
0.49 + 0.09 
0.51 t 0.09 
0.54 + 0.07 
0.49 ‘- 0.17 
0.39 + 0.20 
0.46 + 0.18 
48 
0.50 t 0.1 I 
0.43 2 0.14 
0.39 ? 0.16 
0.43 + 0.16 
0.49 -c 0.17 
0.57 ? 0.14 
52 
0.39 + 0.13 
0.23 2 0.14 
0.26 ? 0.15 
0.33 2 0.18 
0.47 t 0.21 
0.54 + 0.19 
15 
0.48 + 0.07 
0.50 ? 0.10 
0.51 * 0.08 
0.43 + 0.15 
0.36 ? 0.18 
0.42 + 0.18 
kinase in patients with a right coronary infarct-related ar- 
tery. 
When the average regional ejection fraction of the re- 
gions subtended by the infarct-related artery (inferoapical 
and inferolateral for right coronary artery, basal septal and 
apical septal for left anterior descending coronary artery and 
posterolateral for left circumflex coronary artery) was con- 
sidered, there was a trend toward better average infarct 
region ejection fraction in patients treated with t-t-PA than in 
patients treated with streptokinase (0.40 versus 0.36, p = 
0.08). Regression analysis to adjust for the infarct-related 
artery did not change this trend (0.05 < p < 0.06). 
Analysis of subgroups: perfusion status. The ultimate out- 
come of patients receiving thrombolytic therapy depends on 
whether successful reperfusion was achieved. Therefore, 
further subgroup analysis was performed based on perfusion 
status, irrespective of the type of thrombolytic agent. 
There was little difference in mean global left ventricular 
ejection fraction at hospital discharge in 107 patients who 
had sustained reperfusion (Table 3) compared with 122 
patients with nonsustained reperfusion (0.47 versus 0.44, 
p = NS). In contrast, mean regional left ventricular ejection 
fraction was better in the inferolateral segments (0.52 versus 
No. of patients 
Global 
Regional 
Basal septal 
Apical septal 
lnferoapical 
lnferolateral 
Posterolateral 
71 I58 
0.47 + 0.13 0.45 It 0.13 
0.36 + 0.17 0.35 + 0.17 
0.36 2 0.18 0.38 k 0.17 
0.41 + 0.18 0.40 + 0.19 
0.51 2 0.18 0.47 t 0.21 
0.58 ? 0.15 0.54 5 0.17 
0.45, p = 0.01) and the posterolateral segments (0.58 versus 
0.53, p = 0.02) in patients with sustained reperfusion com- 
pared with patients with nonsustained reperfusion. There 
was a trend toward better mean regional ejection fraction in 
the inferoapical segments (0.43 versus 0.38, p = 0.09). When 
the average regional ejection fraction for the infarct region 
subtended by the infarct-related artery was considered, 
infarct regional ejection fraction tended to be better, but did 
not show a statistical trend, as defined for this analysis, in 
patients with sustained reperfusion (0.40 versus 0.36, p = 
0.17). Regression analysis to adjust for the infarct-related 
artery enhanced the statistical significance of this difference 
(p < 0.01). 
When analyzed according to reperfusion status of the 
infurct-related artery, a trend toward improvement of global 
left ventricular ejection fraction was found in patients with a 
left anterior descending coronary artery infarct (sustained 
versus nonsustained reperfusion: 0.41 versus 0.37, p = 0.07). 
A similar trend was found in patients with a right coronary 
artery infarct (sustained versus nonsustained reperfusion: 
0.54 versus 0.49, p = 0.06). The difference observed in 
patients with a left circumflex coronary artery infarct was 
based on a smaller number of patients and never achieved an 
appreciable statistical trend, as defined for this analysis. 
Effect of the presence of collateral vessels on global and 
regional ventricular function (Table 5). There was no differ- 
ence in mean global left ventricular ejection fraction in 
patients with and those without collateral vessels to the 
infarct zone (0.47 versus 0.45, p = NS). Regional left 
ventricular ejection fraction in the posterolateral segment 
was better in patients with collateral vessels (0.58 versus 
0.54, p = 0.05) than in patients without collateral circulation 
to the infarct zone. However, there were no appreciable 
differences in the remaining segments: basal septal, apical 
septal. inferoapical and inferolateral in patients with and 
without collateral vessels to the infarct region. When aver- 
age myocardial infarct regional ejection fraction for the 
regions subtended by the infarct artery was considered, 
there was no difference between patients with collateral 
circulation as opposed to those without (0.39 versus 0.38, 
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p = NS), and no statistical significance emerged with adjust- 
ment for the infarct-related artery. 
Discussion 
Thrombolysis and regional left ventricular function. The 
ultimate goal of thrombolytic therapy in acute myocardial 
infarction is to salvage jeopardized ischemic myocardium 
and, by so doing, improve short- and long-term prognosis. 
Because left ventricular performance is a determinant of 
postinfarction prognosis, assessment of global and regional 
left ventricular function is appropriate for evaluating the 
effects of thrombolytic therapy. The evaluation of regional 
left ventricular function is important because segmental 
improvement of left ventricular function is not always re- 
flected by improvement of global left ventricular ejection 
fraction (18). Compensating hyperkinesia in the noninfarct 
zone may subside, while function in the infarct zone itself 
improves. In the present study, in addition to global left 
ventricular ejection fraction, we employed a count-based 
regional left ventricular ejection fraction to evaluate regional 
left ventricular function. 
Radionuclide ventriculograpby. In Phase I of the TIMI 
trial, both contrast ventriculography and radionuclide ven- 
triculography were performed. Although contrast ventricu- 
lography has the advantage of higher resolution images 
compared with radionuclide studies, radionuclide studies 
have the advantage of being less invasive and hence easier to 
perform in large numbers of patients. Another advantage, 
although not employed in TIM1 Phase I, is that radionuclide 
ventriculography can be combined with exercise evaluation 
to obtain further information about the existence of residual 
ischemic myocardium and prognosis (1 l-13). 
rt-PA compared with streptokinase. In the present study, 
global and regional left ventricular function were compared 
in patients treated with streptokinase or rt-PA. In addition, 
comparisons were made in several nonrandomized sub- 
groups (that is, between patients with sustained or non- 
sustained reperfusion, among patients with different infarct- 
related arteries and between patients with or without 
collateral circulation). Although significantly more success- 
ful reperfusion was observed in patients treated with rt-PA 
compared with those treated with streptokinase, mean dif- 
ferences in global left ventricular ejection fraction between 
the two patient groups were not statistically significant. 
However, trends in regional left ventricular ejection fraction 
favored patients who received rt-PA, and average regional 
ejection fraction in the specific infarct regions favored pa- 
tients treated with rt-PA over patients treated with strepto- 
kinase . 
Reperfusion status. When patients were analyzed accord- 
ing to reperfusion status, patients who had successful sus- 
tained reperfusion of the infarct-related artery had signifi- 
cantly better regional left ventricular function than did 
patients who did not have reperfusion. When patients were 
analyzed according to the specific infarct-related coronary 
artery, trends toward better global left ventricular ejection 
fraction were observed in patients with a right coronary 
artery or left anterior descending coronary infarct who had 
sustained reperfusion. The possible benefit to patients with 
sustained reperfusion must be interpreted with caution be- 
cause these patients were selected by a definition that 
included survival for 3 weeks after study entry. These 
patients could be expected by their selection to have better 
cardiac function in addition to any effects of reperfusion. 
Study design. All observed differences in global and 
regional function were rather modest. It is likely that this 
finding is related to the TIM1 Phase I protocol, which was 
designed to evaluate the relative efficacy of intravenous 
streptokinase and intravenous t-t-PA in achieving throm- 
bolysis and reperfusion of infarct-related arteries. Because 
this protocol required performance of coronary angiography 
before initiation of thrombolytic therapy, many patients had 
relatively late initiation of reperfhsion at a time when the 
chances for myocardial salvage were diminished. In addi- 
tion, TIMI Phase 1 was terminated early because of the 
highly significant difference in the primary end point: reper- 
fusion rate. This action reduced the total number of patients 
available for ventricular function analysis. The present find- 
ings favoring treatment with rt-PA are not due to the 
relatively late initiation of therapy in the total study group. 
Reperfusion rates were also better for r&PA than for strep- 
tokinase in patients treated within 4 h of the onset of chest 
pain (Table 2). 
Previous reports. Similar modest changes in global and 
regional function were previously reported in the contrast 
ventriculographic analysis of TIMI Phase I (4) and in several 
other trials involving intracoronary (14-26) and intravenous 
(27-30) thrombolytic therapy. However, in TIM1 Phase I (4), 
contrast angiographic differences in left ventricular function 
were demonstrated only according to reperfusion status and 
by paired data analysis (that is, acute phase ventriculogram 
versus discharge ventriculogram). Moreover, the present 
study differs from the previous contrast angiographic study 
by the more complete data collection and the larger number 
of patients involved. Differences between treatment groups 
in average infarct region ejection fraction found in this study 
at the time of hospital discharge were not looked for in the 
contrast angiographic study (4). Differences between treat- 
ment groups for global ejection fraction were not statistically 
significant in the contrast angiographic study (4) or in the 
present study. 
Conclusions. This is the first study involving a direct 
comparison of rt-PA and streptokinase thrombolytic therapy 
in which a strong suggestion exists that there is a relation 
between therapeutic efficacy assessed by infarct-related ar- 
tery patency and functional improvement. Patients treated 
with rt-PA demonstrated better infarct region ejection frac- 
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tion than did patients treated with streptokinase. However, 
this study was conducted with a sufficient number of patients 
to detect differences in reperfusion, and the differences in 
infarct region ejection fraction approached but did not 
exceed conventional significance (p = 0.05) levels. In pa- 
tients who had successful thrombolysis and sustained reper- 
fusion of the infarct-related artery, radionuclide angiocardio- 
graphic studies at hospital discharge demonstrated 
improvement of regional left ventricular function within the 
territory of the infarct artery, as well as trends toward 
improved global left ventricular function for infarcts related 
to the right coronary artery and infarcts related to the left 
anterior descending coronary artery. This study also illus- 
trates the potential of quantitative radionuclide angiocardio- 
graphy at hospital discharge for evaluating the benefits of 
early thrombolytic therapy on global and regional left ven- 
tricular function. 
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